FDA Panel Okays Keytruda’s Hepatocellular Carcinoma Indication, But Splits On Opdivo

 
• By Brenda Sandburg
  
Opposite results
FDA advisory panel reaches opposite conclusions on Keytruda, Opdivo HCC indication • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers